Murthy VL, Piaggi P, Lin P, et al. Human Physiologic Responses to Insulin in Indigenous Americans Identify a Metabolic Susceptibility Profile Linked to Diabetes. Diabetes care. 2025;48(7):1260-1272. doi:10.2337/dc25-0151
Publications
Braun F, Mandel AM, Blomberg L, et al. Loss of genome maintenance is linked to mTOR complex 1 signaling and accelerates podocyte damage. JCI insight. 2025;10(12). doi:10.1172/jci.insight.172370
Beccari MS, Arnold-Garcia O, Baughn MW, et al. Stathmin-2 enhances motor axon regeneration after injury independent of its binding to tubulin. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(21):e2502294122. doi:10.1073/pnas.2502294122
Kreienkamp RJ, Deutsch AJ, Huerta-Chagoya A, et al. Type 1 Diabetes Polygenic Scores Improve Diagnostic Accuracy in Pediatric Diabetes Care. Hormone research in paediatrics. 2025:1-9. doi:10.1159/000546445
Shaw K, Bernards R, Stegmaier K, Varmus H, Sellers WR. Prospects for understanding and exploiting the consequences of hyperactivation lethality. Trends in cancer. 2025;11(7):619-628. doi:10.1016/j.trecan.2025.04.009
Kirmani S, Huan T, Van Amburg JC, et al. Epigenome-wide DNA methylation association study of CHIP provides insight into perturbed gene regulation. Nature communications. 2025;16(1):4678. doi:10.1038/s41467-025-59333-w
Leventhal MJ, Zanella CA, Kang B, et al. An integrative systems-biology approach defines mechanisms of Alzheimer’s disease neurodegeneration. Nature communications. 2025;16(1):4441. doi:10.1038/s41467-025-59654-w
Wu W, Ishamuddin SH, Quinn TW, et al. High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples. Nature biomedical engineering. 2025. doi:10.1038/s41551-025-01408-6
Bragazzi NL, Zhang L, Omarov M, Georgakis MK. Genetic Risk Scores in Stroke Research and Care. Stroke. 2025;56(8):2327-2336. doi:10.1161/STROKEAHA.125.050961
Perkins DO, Jeffries CD, Clark SR, et al. Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations. Schizophrenia (Heidelberg, Germany). 2025;11(1):78. doi:10.1038/s41537-025-00610-4